Recent studies suggest that patients with CRLF2 rearrangements exhibit resistance to glucocorticoids, a key component of ALL therapy, but this resistance can be overcome with MEK or Akt inhibition, presenting new avenues for targeted treatment [140]. The gene discussed is CRLF2; the disease is acute lymphoblastic leukemia.